Clinical Trial Update: A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 1/2 study of CBP-1019, a bi-ligand-drug conjugate, in patients with advanced solid tumors including breast, lung, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• CBP-1019 (Bi-Ligand-Drug Conjugate)

Snippet

Sponsor: Coherent Biopharma (Hefei) Co., Ltd. | Conditions: Cancer, Breast, Cancer, Lung | Phase 1, Phase 2 | Status: UNKNOWN